MGTA News and Press, Magenta Therapeutics Inc. From 04/30/20

Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The ...

–Magenta will present seven abstracts showcasing findings across clinical and pre-clinical pipeline, including five oral and two poster presentations – –MGTA-145 clinical data will demonstrate rapid, single-day mobilization of large numbers of human HSCs that can b...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medica...

MGTA-117 conditioning ADC-based program on track for initial clinical data in 2021 MGTA-145 stem cell mobilization Phase 1 program met all safety and efficacy endpoints and enrollment is complete in renal pharmacokinetic study; potential for initial Phase 2 data in 2020 CD45-ADC p...

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the 40 th annual Cowen Health Care Confe...

Magenta Therapeutics (NASDAQ: MGTA ) has completed dosing in its Phase 1 trial of stem cell mobilization therapy clinical candidate, MGTA-145, as well as updated clinical data from the trial at the Transplant and Cellular Therapy Annual Meeting in Orlando, Florida. More news on: Magenta ...

– MGTA-117 ADC clinical candidate for conditioning showed broad tolerability and wide pre-clinical safety margins – – MGTA-117 demonstrated robust anti-tumor activity in xenograft models from patients with refractory leukemia – – Magenta plans to mov...

– Updated data from the Phase 1 study in healthy subjects show that MGTA-145, in combination with plerixafor, met all primary and secondary endpoints – – Median of 4.1 million CD34+ cells/kg collected in a single day from eight subjects – – Magenta p...

Thinly traded Magenta Therapeutics (NASDAQ: MGTA ) is up  3%  premarket on light volume in reaction to updated data from a Phase 2 clinical trial evaluating cell therapy MGTA-456 in patients with severe inherited metabolic disorders, including cerebral adrenoleukodystrophy (cAL...

-- Additional data from Phase 2 study show that MGTA-456 demonstrates clinically meaningful durable benefits for patients with inherited metabolic disorders one year following treatment – -- Magenta intends to complete enrollment in Phase 2 in 2020 and continue dialogue with the...